Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04566445




Registration number
NCT04566445
Ethics application status
Date submitted
9/09/2020
Date registered
28/09/2020
Date last updated
20/03/2024

Titles & IDs
Public title
HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
Scientific title
HORIZON: A Phase II, Open-label, Outcomes-assessor Masked, Multicentre, Randomised, Controlled Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Secondary ID [1] 0 0
CPPY988A12201
Secondary ID [2] 0 0
GT005-03
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Dry Age-related Macular Degeneration 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - GT005: Medium Dose
Treatment: Drugs - GT005: High Dose

Experimental: GT005 Medium Dose - Approximately 83 subjects are planned, with subjects randomised to GT005 Medium Dose.

Experimental: GT005 High Dose - Approximately 83 subjects are planned, with subjects randomised to GT005 High Dose.

No Intervention: Untreated control - Approximately 83 subjects are planned, with subjects randomised to untreated control.


Treatment: Drugs: GT005: Medium Dose
The study will test two doses of GT005: Medium Dose and High Dose.

Treatment: Drugs: GT005: High Dose
The study will test two doses of GT005: Medium Dose and High Dose.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression of geographic atrophy
Timepoint [1] 0 0
72 weeks
Secondary outcome [1] 0 0
Progression of geographic atrophy
Timepoint [1] 0 0
96 weeks
Secondary outcome [2] 0 0
Evaluation of the safety and tolerability of GT005
Timepoint [2] 0 0
96 weeks
Secondary outcome [3] 0 0
Evaluation of the effect of GT005 on retinal anatomical measures
Timepoint [3] 0 0
96 weeks
Secondary outcome [4] 0 0
Evaluation of the effect of GT005 on functional measures
Timepoint [4] 0 0
96 weeks
Secondary outcome [5] 0 0
Evaluation of the effect of GT005 on functional measures
Timepoint [5] 0 0
96 weeks
Secondary outcome [6] 0 0
Evaluation of the effect of GT005 on visual function
Timepoint [6] 0 0
96 weeks
Secondary outcome [7] 0 0
Evaluation of the effect of GT005 on visual function
Timepoint [7] 0 0
96 weeks
Secondary outcome [8] 0 0
Evaluation of the effect of GT005 on patient-reported outcomes
Timepoint [8] 0 0
96 weeks

Eligibility
Key inclusion criteria
1. Able and willing to give written informed consent

2. Age =55 years

3. a. In Stage 1: Have a clinical diagnosis of GA secondary to AMD in the study eye, as
determined by the Investigator, and a diagnosis of AMD in the contralateral eye; b. In
Stage 2: Have a clinical diagnosis of GA secondary to AMD in the study eye, as
determined by the Investigator, that is non-foveal, as determined by the central
reading centre, or has a CFI rare variant genotype and meets inclusion criteria 3a,
and a diagnosis of AMD in the contralateral eye (except if monocular)

4. GA lesion(s) within an acceptable size on FAF, in the study eye

5. The GA lesion in the study eye must reside completely within the FAF image

6. Up to 25% of the enrolled study population are permitted to have CNV in the fellow eye

7. Have a BCVA of =24 letters (6/95 or 20/320 Snellen acuity equivalent), using ETDRS
charts, in the study eye

8. a. In Stage 1: Meet one of the pre-specified AMD genetic subgroup criteria; b. In
Stage 2: Genotyping is not required for study eligibility

9. Able to attend all study visits and complete the study procedures

10. Women of child-bearing potential must have a negative pregnancy test within 2 weeks
prior to randomisation (not required for postmenopausal women) or provide
documentation of being surgically sterilised
Minimum age
55 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. a. In Stage 1: Carriers of excluded genetic variants; b. In Stage 2: Subjects are
excluded if they have a clinical diagnosis of Stargardt Disease or other retinal
dystrophies

2. Have a history, or evidence, of CNV in the study eye

3. Presence of moderate/severe or worse non-proliferative, diabetic retinopathy in the
study eye

4. Have history of vitrectomy, sub-macular surgery, or macular photocoagulation in the
study eye

5. History of intraocular surgery in the study eye within 12 weeks prior to Visit 1

6. Have clinically significant cataract that may require surgery during the study period
in the study eye

7. Presence of moderate to severe glaucomatous optic neuropathy, uncontrolled intraocular
pressure (IOP), despite use of two or more topical agents; or a history of
glaucoma-filtering or valve surgery

8. Axial myopia of greater than -8 diopters in the study eye

9. Have received any investigational product for the treatment of GA within the past 6
months or 5 half-lives (whichever is longer), other than nutritional supplements such
as the age-related eye disease study (AREDS) formula

10. Have received a gene or cell therapy at any time.

11. Have a contraindication to the protocol specified corticosteroid regimen

12. Are unwilling to use two forms of contraception (one of which being a barrier method)
for 90 days post-dosing, if relevant

13. Active malignancy within the past 12 months, except for appropriately treated
carcinoma in situ of the cervix, non-melanoma skin carcinoma, or prostate cancer with
a stable prostate-specific antigen (PSA) = 12 months

14. Have any other significant ocular or non-ocular medical or psychiatric condition
which, in the opinion of the Investigator, may either put the subject at risk or may
influence the results of the study

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
28/09/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/05/2024
Actual
Sample size
Target
Accrual to date
Final
255
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Sydney Hospital and Sydney Eye Hospital - Sydney
Recruitment hospital [2] 0 0
The University of Melbourne - The Centre for Eye Research Australia (CERA) - Melbourne E.
Recruitment postcode(s) [1] 0 0
2000 - Sydney
Recruitment postcode(s) [2] 0 0
3002 - Melbourne E.
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Nevada
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Oregon
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
South Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Tennessee
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Utah
Country [23] 0 0
United States of America
State/province [23] 0 0
Washington
Country [24] 0 0
France
State/province [24] 0 0
Dijon
Country [25] 0 0
France
State/province [25] 0 0
Marseille
Country [26] 0 0
France
State/province [26] 0 0
Nantes
Country [27] 0 0
Germany
State/province [27] 0 0
Bonn
Country [28] 0 0
Germany
State/province [28] 0 0
Düsseldorf
Country [29] 0 0
Germany
State/province [29] 0 0
Lübeck
Country [30] 0 0
Germany
State/province [30] 0 0
Tuebingen
Country [31] 0 0
Poland
State/province [31] 0 0
Bydgoszcz
Country [32] 0 0
Spain
State/province [32] 0 0
Barcelona
Country [33] 0 0
Spain
State/province [33] 0 0
Madrid
Country [34] 0 0
Spain
State/province [34] 0 0
Pamplona
Country [35] 0 0
United Kingdom
State/province [35] 0 0
London
Country [36] 0 0
United Kingdom
State/province [36] 0 0
Oxford
Country [37] 0 0
United Kingdom
State/province [37] 0 0
Sunderland

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Gyroscope Therapeutics Limited
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Novartis Pharmaceuticals
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this clinical study is to evaluate the safety and efficacy of two doses of
GT005 administered as a single subretinal injection in subjects with geographic atrophy
secondary to age-related macular degeneration (AMD).
Trial website
https://clinicaltrials.gov/ct2/show/NCT04566445
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04566445